Arizona Tribune - Onco-Innovations Attends University of Alberta's 2025 Innovation Awards

This year marked the first time the University of Alberta has included technology licensees, highlighting the institution's growing focus on industry collaboration and the advancement of technologies from lab to market. In 2024, Onco-Innovations licensed a portfolio of oncology-related technologies from the University, supporting the translation of university research into next-generation cancer therapeutics.

"We were honored to join the University of Alberta in a shared commitment to advancing oncology innovation. The University's decades of foundational research, combined with our mission to pursue and commercialize transformative cancer therapeutics, represent the very best of Canadian scientific collaboration," stated Thomas O'Shaughnessy, Chief Executive Officer of Onco-Innovations.

Onco-Innovations and the University of Alberta entered into an exclusive license agreement in 2024 granting Onco the right to develop and commercialize the PNKP Inhibitor Technology, a pioneering approach designed to enhance the effectiveness of DNA-damage-based cancer treatments. Developed through more than 15 years of research at the University of Alberta, the PNKP Inhibitor Technology has resulted in nine issued patents, representing a major advancement in targeting DNA repair mechanisms in cancer cells.

The PNKP Inhibitor Technology is designed to sensitize cancer cells to chemotherapy and radiation by delaying DNA repair, thereby improving treatment outcomes. In both in-vitro and in-vivo studies, the technology has demonstrated strong potential across multiple cancer types. Through its collaboration with the University of Alberta, Onco-Innovations continues to advance preclinical development and IND-enabling studies, with the goal of progressing this innovative platform toward clinical evaluation.

"This recognition reflects the importance of translating strong academic science into real therapeutic application. As we advance this platform, the growing body of mechanistic and preclinical evidence continues to reinforce its potential to redefine how DNA repair pathways are targeted in cancer treatment," said Dr. Islam Mohamed, Chair of the Scientific & Clinical Advisory Board.

The Company also announces that its Board of Directors has approved the issuance of a total of 60,000 Restricted Share Units ("RSUs") to certain directors of the Company pursuant to its equity incentive plan (the "Plan").

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, focussed on oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has an exclusive license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
[email protected]

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

R.Garcia--AT